Market Overview

Seattle Genetics Confirms FDA Orphan Drug Status for ADCETRIS

Share:
Related SGEN
Seattle Genetics Offers Data Supporting Antibody-Drug Conjugate, Novel Immuno-Oncology Programs at AACR Meeting
The Most Notable Insider Buys And Sells Of Last Week
Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results - Earnings Call Transcript (Seeking Alpha)

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL). Seattle Genetics and its ADCETRIS collaborator, Millennium: The Takeda Oncology Company, are conducting the ALCANZA trial, a phase III clinical trial of ADCETRIS for patients with CD30-positive relapsed CTCL, including MF. ADCETRIS is not approved for the treatment of CTCL.

Posted-In: News FDA

 

Related Articles (SGEN)

View Comments and Join the Discussion!